At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of ...
Brazil's Health Regulatory Agency (Anvisa) approved on Monday the use of the drug Sunlenca (lenacapavir) for HIV-1 prevention ...
Dec 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling drug Biktarvy in a late-stage ...
Though Charlie Sheen's HIV status has been "completely manageable," the award-winning actor said he once found a "really good" solution that never came to fruition. During an appearance on the "Howie ...
New York City health department officials are concerned after recently released data showed a slight uptick in HIV cases – which comes as the federal government proposes cutting funding to HIV ...
Masonia Traylor folded into a ball in the corner of the patient room. "No," the 23-year-old screamed, over and over again. She was HIV-positive. It came as a surprise to the now 38-year-old from ...
On World AIDS Day, advocates warn federal cuts could reverse progress. Carole Treston had been a nurse early in her career when she and her mother traveled to Washington, D.C., and saw the AIDS ...
People infected with HIV must take antiretroviral drugs for life. But promising trials using engineered antibodies suggest that "functional cures" may be in reach. When you purchase through links on ...
A new study from UC San Francisco shows it may be possible to control HIV without long-term antiviral treatment — an advance that points the way toward a possible cure for a disease that affects 40 ...
A new study from UC San Francisco shows it may be possible to control HIV without long-term antiviral treatment—an advance that points the way toward a possible cure for a disease that affects 40 ...
South Africa, Eswatini and Zambia on Monday began administering a groundbreaking HIV-prevention injection in the drug's first public rollouts in Africa, which has the world's highest HIV burden.